Status:
COMPLETED
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study
Lead Sponsor:
The Emmes Company, LLC
Collaborating Sponsors:
National Eye Institute (NEI)
Allergan
Conditions:
Macular Edema, Cystoid
Retinal Vein Occlusion
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The SCORE Study will compare the effectiveness and safety of standard care to intravitreal injection(s) of triamcinolone for treating macular edema (swelling of the central part of the retina) associa...
Detailed Description
Macular edema is a major cause of vision loss in patients with CRVO and BRVO. Both CRVO and BRVO are common retinal problems and are caused by a blockage in one of the large retinal veins (central ret...
Eligibility Criteria
Inclusion
- Participants with macular edema (swelling of the central part of the retina) associated with central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).
- Individuals, 18 years of age or older, willing to provide consent may be eligible for the SCORE Study.
Exclusion
- refer to SCORE Study website at https://web.emmes.com/study/score/ for listing.
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
682 Patients enrolled
Trial Details
Trial ID
NCT00105027
Start Date
October 1 2004
End Date
February 1 2009
Last Update
July 2 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Wisconsin
Madison, Wisconsin, United States, 53711